Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия; 2ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава России, Москва, Россия; 3ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия; 4НИКИ педиатрии им. акад. Ю.Е. Вельтищева ФГБОУ ВО «РНИМУ им. Н.И. Пирогова» Минздрава России asus99@mail.ru
Список исп. литературыСкрыть список 1. Ference BA, Ginsberg HN, Graham I et al. Low density lipoprotein cause atherosclerotic cardiovascular disease. Evidence from genetic, epidemiologic and clinical studies. A Consensus Statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017; 1–14. 2. Borén J, Chapman MJ, Krauss RM et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2020. PII: ehz962. DOI: 10.1093/eurheartj/ehz962 3. Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis 2019; 290: 140–205. DOI: 10.1016/j.atherosclerosis.2019.08.014 4. Grundy SM, Stone NJ, Bailey C et al. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139 (25): e1082-e1143. 5. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22. 6. Cholesterol Treatment Trialists (CTT) Collaborators Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670–81. 7. Cholesterol Treatment Trialists (CTT) Collaborators The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581–90. 8. Cholesterol Treatment Trialists (CTT) Collaborators. Fulcher J. O’Connel R, Voysey M. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomized trials. Lancet 2015; 385: 1397–405. 9. Goldstein JL, Brown MS. Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. Proc Natl Acad Sci USA 1973; 70: 2804–8. 10. Rader D, Cohen J, Hobbs H. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Investig 2003; 112 (11): 1795–1803. 11. Santos RD, Gidding SS, Hegele RA et al. International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Defining Severe Familial Hypercholesterolaemia and the Implications for Clinical Management: A Consensus Statement From the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes Endocrinol 2016; 4 (10): 850–61. DOI: 10.1016/S2213-8587(16)30041-9 12. Cuchel M, Bruckert E, Ginsberg HM et al. Homozygous familial hypercholesterolaemia:new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014; 35 (32): 2146–57. DOI: 10.1093/eurheartj/ehu27 13. Wiegman A, Gidding SS, Watts GF et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 2015; 21; 36 (36): 2425–37. DOI: 10.1093/eurheartj/ehv157 14. Зафираки В.К., Космачева Е.Д., Захарова И.Н. и др. Гомозиготная семейная гиперхолестеринемия. Современные аспекты патогенеза, диагностики и терапии. Медицинский совет. 2018; 17: 253–9. [Zafiraki V.К., Kosmacheva Е.D., Zakharova I.N. et al. Homozygous familial hypercholesterolemia: modern aspects of pathogenesis, diagnostics and treatment. Meditsinskiy sovet = Medical Council. 2018; (17): 253–60 (in Russian).] 15. Сусеков А.В., Лугинова З.Г., Мешков А.Н. и др. Консилиум у 9-летнего мальчика с уровнем холестерина 20 ммоль/л: от постановки диагноза к эффективному лечению. Медицинский Совет. 2014; 12: 106–10. [Susekov A.V., Luginova Z.G., Meshkov A.N. et al. Konsilium u 9-letnego mal'chika s urovnem kholesterina 20 mmol'/l: ot postanovki diagnoza k effektivnomu lecheniiu. Meditsinskii Sovet. 2014; 12: 106–10 (in Russian).] 16. Сусеков А.В., Яфарова А.А., Щербакова М.Ю., Мешков А.Н. Регресссия ксантоматоза у 12-летнего пациента с гомозиготной формой семейной гиперхолестеринемии: клинический случай. Consillum Medicum. Педиатрия (прил). 2016; 3: 103–18. [Susekov A.V., Iafarova A.A., Shcherbakova M.Iu., Meshkov A.N. Regresssiia ksantomatoza u 12-letnego patsienta s gomozigotnoi formoi semeinoi giperkholesterinemii: klinicheskii sluchai. Consillum Medicum. Pediatriia (pril). 2016; 3: 103–18 (in Russian).] 17. Raal FJ, Honarpour N, Blom DJ et al. TESLA Investigators Inhibition of PCSK9 with evolocumab in homozygous familial ypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 385 (9965): 341–50. DOI: 10.1016/S0140-6736(14)61374-X 18. Blom DJ, Fayad ZA, Kastelein JJ et al. LOWER investigators. LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design. J Clin Lipidol 2016; 10 (2): 273–82. DOI: 10.1016/j.jacl.2015.11.011 19. Santos RD, Duell PB, East C et al. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur Heart J 2015; 36 (9): 566–75. DOI: 10.1093/eurheartj/eht549 20. Stefanutti C, Thomson GR. Lipoprotein Apheresis in the Management of Familial Hypercholesterolaemia: Historical Perspective and Recent Advances. Curr Atheroscler Rep 2015; 17: 465. DOI 10.1007/s11883-014-0465-6 21. Raal FJ, Hoving GK, Blom D et al. Long-term Treatment With Evolocumab Added to Conventional Drug Therapy, With or Without Apheresis, in Patients With Homozygous Familial Hypercholesterolaemia: An Interim Subset Analysis of the Open-Label TAUSSIG Study. Lancet Diabetes Endocrinol 2017; 5 (4): 280–90.